Live Markets »News & Advice»Market News»Market News Details
Market News Details

AstraZeneca Pharma inks distribution pact with Abbott for diabetes drug

Press Trust of India/New Delhi 07 Dec 18 | 10:50 AM

Representative image

Drug firm AstraZeneca Pharma India Friday said it has entered into a distribution agreement with Abbott Healthcare for distribution of diabetes medicine Dapagliflozin in India.

Related Stories

    No Related Stories Found
Widgets Magazine

Dapagliflozin, an innovative Type 2 diabetes medicine, is AstraZeneca Pharma's leading diabetes medicine.

"Under the agreement, Abbott will promote and distribute Dapagliflozin under the brand name GLEDEPA. Abbott will also gain the rights to promote and distribute the combination of dapagliflozin with metformin under the brand name GLEDEPA MET," AstraZeneca Pharma said in a regulatory filing.

AstraZeneca Pharma, which did not share financial details of the agreement, said it will continue to promote and distribute dapagliflozin under the brand name Forxiga and combination of dapagliflozin with metformin under the brand name Xigduo.

Shares of AstraZeneca Pharma were trading 0.54 per cent higher at Rs 1,341.35 apiece on BSE.

Widgets Magazine


Company Price Gain (%)
IndusInd Bank1,572.003.59
Yes Bank141.702.90
ICICI Bank416.252.65
St Bk of India348.102.13
Power Grid Corpn185.701.98


Currently No Poll Available.

Online Portfolio

You can create Online Portfolio here using the below button.

Widgets Magazine